Alkylating antineoplastic agent

Revision as of 15:04, 1 June 2009 by Brian Blank (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Alkylating antineoplastic agent

Articles

Most recent articles on Alkylating antineoplastic agent

Most cited articles on Alkylating antineoplastic agent

Review articles on Alkylating antineoplastic agent

Articles on Alkylating antineoplastic agent in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alkylating antineoplastic agent

Images of Alkylating antineoplastic agent

Photos of Alkylating antineoplastic agent

Podcasts & MP3s on Alkylating antineoplastic agent

Videos on Alkylating antineoplastic agent

Evidence Based Medicine

Cochrane Collaboration on Alkylating antineoplastic agent

Bandolier on Alkylating antineoplastic agent

TRIP on Alkylating antineoplastic agent

Clinical Trials

Ongoing Trials on Alkylating antineoplastic agent at Clinical Trials.gov

Trial results on Alkylating antineoplastic agent

Clinical Trials on Alkylating antineoplastic agent at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alkylating antineoplastic agent

NICE Guidance on Alkylating antineoplastic agent

NHS PRODIGY Guidance

FDA on Alkylating antineoplastic agent

CDC on Alkylating antineoplastic agent

Books

Books on Alkylating antineoplastic agent

News

Alkylating antineoplastic agent in the news

Be alerted to news on Alkylating antineoplastic agent

News trends on Alkylating antineoplastic agent

Commentary

Blogs on Alkylating antineoplastic agent

Definitions

Definitions of Alkylating antineoplastic agent

Patient Resources / Community

Patient resources on Alkylating antineoplastic agent

Discussion groups on Alkylating antineoplastic agent

Patient Handouts on Alkylating antineoplastic agent

Directions to Hospitals Treating Alkylating antineoplastic agent

Risk calculators and risk factors for Alkylating antineoplastic agent

Healthcare Provider Resources

Symptoms of Alkylating antineoplastic agent

Causes & Risk Factors for Alkylating antineoplastic agent

Diagnostic studies for Alkylating antineoplastic agent

Treatment of Alkylating antineoplastic agent

Continuing Medical Education (CME)

CME Programs on Alkylating antineoplastic agent

International

Alkylating antineoplastic agent en Espanol

Alkylating antineoplastic agent en Francais

Business

Alkylating antineoplastic agent in the Marketplace

Patents on Alkylating antineoplastic agent

Experimental / Informatics

List of terms related to Alkylating antineoplastic agent

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

An alkylating antineoplastic agent is an alkylating agent that attaches an alkyl group to DNA.

Since cancer cells generally proliferate unrestrictively more than do healthy cells they are more sensitive to DNA damage, and alkylating agents are used clinically to treat a variety of tumours.

Agents acting nonspecifically

Some alkylating agents are active under conditions present in cells; and the same mechanism that makes them toxic allows them to be used as anti-cancer drugs. They stop tumour growth by cross-linking guanine nucleobases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. These drugs act nonspecifically.

Agents require activation

Some of them require conversion into active substances in vivo (e.g. cyclophosphamide).

Cyclophosphamide is one of the most potent immunosuppressive substances. In small dosages, it is very efficient in the therapy of systemic lupus erythematosus, autoimmune hemolytic anemias, Wegener's granulomatosis and other autoimmune diseases. High dosages cause pancytopenia and hemorrhagic cystitis.

Dialkylating agents, limpet attachment, and monoalkylating agents

Dialkylating agents can react with two different 7-N-guanine residues and if these are in different strands of DNA the result is cross-linkage of the DNA strands, which prevents uncoiling of the DNA double helix. If the two guanine residues are in the same strand the result is called limpet attachment of the drug molecule to the DNA.

Monoalkylating agents can react only with one 7-N of guanine.

Limpet attachment and monoalkylation do not prevent the separation of the two DNA strands of the double helix but do prevent vital DNA processing enzymes from accessing the DNA. The final result is inhibition of cell growth or stimulation of apoptosis, cell suicide.

Examples

In the Anatomical Therapeutic Chemical Classification System, alkylating agents are classified under L01A.

Alkylating agents activated by cytochrome p-450:

Other selected examples:

External links

Template:SIB

Template:WS